Eupraxia Pharmaceuticals (EPRX) vs Oculis (OCS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Eupraxia Pharmaceuticals (EPRX) has outperformed Oculis (OCS) over the past year, gaining 29.2% versus a loss of 55.4%. Oculis is the larger company by market cap ($531.5 million vs $491.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EPRX | OCS |
|---|---|---|
| Share price | $7.44 | $8.63 |
| Market cap | $491.59M | $531.51M |
| 1-day change | -4.37% | +1.53% |
| YTD return | +3.05% | -57.44% |
| 1-year return | +29.24% | -55.40% |
| 5-year return | — | -13.44% |
| EPS (TTM) | $-1.02 | $-1.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.32 | $34.48 |
| 52-week low | $5.25 | $8.30 |
| Distance from 52-week high | -20.17% | -74.97% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +119.76% | +322.83% |
| Average volume | 567.95K | 258.13K |
| Shares outstanding | 66.07M | 61.59M |
| Employees | 49 | 60 |
| Sector | Health Care | Health Care |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EPRX has outperformed OCS by 84.6 percentage points over the past year.
About Eupraxia Pharmaceuticals
EPRX stock →Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.
Health Care · Pharmaceuticals and Biotechnology · 49 employees
About Oculis
OCS stock →Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
EPRX vs OCS FAQ
Which is bigger, Eupraxia Pharmaceuticals or Oculis?
Oculis (OCS) is larger, with a market capitalization of $531.51M compared with $491.59M for Eupraxia Pharmaceuticals (EPRX).
Which stock has performed better over the past year, EPRX or OCS?
EPRX returned +29.24% over the past 12 months, compared with -55.40% for OCS (price return, excluding dividends). Past performance does not predict future results.
Are Eupraxia Pharmaceuticals and Oculis in the same industry?
Both are in the Health Care sector, but in different industries: Pharmaceuticals and Biotechnology for Eupraxia Pharmaceuticals and Biotechnology: Pharmaceutical Preparations for Oculis.